Auer M - Search Results

1

Short report: Real-life analysis of the occurrence of persistent, transient, and fluctuating positive titres of neutralizing anti-drug antibodies in multiple sclerosis patients treated with interferon beta.

Oviedo Querejazu M, Dunn N, Ramanujam R, Ryner M, Auer M, Hyldgaard Jensen PE, Deisenhammer F, Fogdell-Hahn A; ABIRISK consortium. Oviedo Querejazu M, et al. Among authors: auer m. Mult Scler Relat Disord. 2022 Jul;63:103815. doi: 10.1016/j.msard.2022.103815. Epub 2022 Apr 17. Mult Scler Relat Disord. 2022. PMID: 35508100

2

Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: implications for clinical practice.

Hegen H, Auer M, Deisenhammer F. Hegen H, et al. Among authors: auer m. Clin Chem Lab Med. 2014 Sep;52(9):1335-40. doi: 10.1515/cclm-2014-0077. Clin Chem Lab Med. 2014. PMID: 24731954

3

Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity.

Hegen H, Auer M, Zeileis A, Deisenhammer F. Hegen H, et al. Among authors: auer m. Clin Chem Lab Med. 2016 Feb;54(2):285-92. doi: 10.1515/cclm-2015-0253. Clin Chem Lab Med. 2016. PMID: 26079822

4

Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.

Hegen H, Auer M, Deisenhammer F. Hegen H, et al. Among authors: auer m. Expert Opin Drug Metab Toxicol. 2015;11(12):1803-19. doi: 10.1517/17425255.2015.1094055. Epub 2015 Sep 30. Expert Opin Drug Metab Toxicol. 2015. PMID: 26419922 Review.

5

Quantitation of intrathecal immunoglobulin synthesis - a new empirical formula.

Auer M, Hegen H, Zeileis A, Deisenhammer F. Auer M, et al. Eur J Neurol. 2016 Apr;23(4):713-21. doi: 10.1111/ene.12924. Epub 2016 Jan 25. Eur J Neurol. 2016. PMID: 26806360

6

Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.

Auer M, Borena W, Holm-von Laer D, Deisenhammer F. Auer M, et al. J Med Virol. 2017 Jan;89(1):3-9. doi: 10.1002/jmv.24590. Epub 2016 Jun 9. J Med Virol. 2017. PMID: 27253624

7

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.

Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, Deisenhammer F, Reindl M, Berger T. Bsteh G, et al. Among authors: auer m. PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978. eCollection 2016. PLoS One. 2016. PMID: 27391947 Free PMC article.

8

Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter.

Ehling R, Bsteh G, Di Pauli F, Hegen H, Auer M, Obermair K, Wagner M, Deisenhammer F, Reindl M, Berger T. Ehling R, et al. Among authors: auer m. Mult Scler Relat Disord. 2016 Sep;9:150-4. doi: 10.1016/j.msard.2016.07.014. Epub 2016 Jul 27. Mult Scler Relat Disord. 2016. PMID: 27645364

9

Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Hegen H, Auer M, Deisenhammer F. Hegen H, et al. Among authors: auer m. Drugs. 2016 Oct;76(15):1421-1445. doi: 10.1007/s40265-016-0639-3. Drugs. 2016. PMID: 27653757 Review.

10

Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.

Bsteh G, Feige J, Ehling R, Auer M, Hegen H, Di Pauli F, Deisenhammer F, Reindl M, Berger T. Bsteh G, et al. Among authors: auer m. Mult Scler. 2017 Aug;23(9):1241-1248. doi: 10.1177/1352458516675751. Epub 2016 Oct 20. Mult Scler. 2017. PMID: 27765877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

492 results

Search Page

Filters